Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.06. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 | 4.150 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
12.06. | Relief Therapeutics Holding SA: Relief Therapeutics Announces Results of Annual General Meeting | 337 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Announces Results of Annual General Meeting
12.06.2025 / 11:00 CET/CEST
Relief Therapeutics Announces... ► Artikel lesen | |
22.05. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 | 4.804 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Research Update
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
22-May-2025 / 07:00 CET/CEST
Release of... ► Artikel lesen | |
15.05. | Relief Therapeutics Holding SA: Relief Therapeutics Publishes 2025 Annual General Meeting Agenda | 494 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
15.05.2025 / 07:00 CET/CEST
Relief Therapeutics Publishes... ► Artikel lesen | |
RELIEF THERAPEUTICS HOLDING AG ADR Aktie jetzt für 0€ handeln | |||||
10.04. | Relief Therapeutics Holding GAAP EPS of -CHF 1.37, revenue of CHF 9.83B | 7 | Seeking Alpha | ||
10.04. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update | 1.344 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Annual Results
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
10-Apr-2025 / 07:00 CET/CEST
Release of an... ► Artikel lesen | |
07.03. | Relief Therapeutics and Renexxion terminate merger talks | 4 | Pharmaceutical Business Review | ||
06.03. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion | 6.330 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Merger
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
06-March-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
11.02. | Relief Therapeutics to get European patent for investigational drug RLF-TD011 | 19 | Seeking Alpha | ||
11.02. | Relief Therapeutics Holding SA: Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 | 634 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Patent
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
11.02.2025 / 07:00 CET/CEST
Relief... ► Artikel lesen | |
22.01. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US | 4.269 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
22-Jan-2025 / 07:00 CET/CEST
Release of... ► Artikel lesen | |
27.12.24 | Relief Therapeutics Holding SA: Relief Therapeutics Provides Update on Potential Transaction with Renexxion | 791 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Merger
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
27.12.2024 / 07:00 CET/CEST
Relief Therapeutics... ► Artikel lesen | |
16.12.24 | Relief Therapeutics Holding SA: Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial | 541 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Study results
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
16.12.2024 / 07:00 CET/CEST
Relief... ► Artikel lesen | |
13.12.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations | 10.610 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
13-Dec-2024 / 23:00 CET/CEST
Release... ► Artikel lesen | |
11.11.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa | 3.980 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
11-Nov-2024 / 07:00... ► Artikel lesen | |
04.11.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger | 3.024 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Merger
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
04-Nov-2024 / 07:00 CET/CEST
Release of an... ► Artikel lesen | |
29.10.24 | Relief Therapeutics Holding SA: Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE | 506 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Miscellaneous
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
29.10.2024 / 07:00 CET/CEST
Relief... ► Artikel lesen | |
25.10.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents | 4.733 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
25-Oct-2024 / 07:00 CET/CEST
Release... ► Artikel lesen | |
21.10.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment | 3.165 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Patent
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
21-Oct-2024... ► Artikel lesen | |
08.10.24 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa | 3.514 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
08-Oct-2024... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
REVIVE THERAPEUTICS | 0,001 | -94,59 % | Revive Therapeutics Ltd: Revive hopes to conclude bucillamine study by September | ||
QIAGEN | 40,740 | -1,31 % | Kurs von Qiagen NV steigt etwas (41,29 €) | Am Aktienmarkt notiert der Anteilsschein von Qiagen NV derzeit ein wenig fester. Zuletzt zahlten Investoren für das Wertpapier 41,29 Euro. Heute hat sich im Wertpapierhandel die Qiagen NV-Aktie zwischenzeitlich... ► Artikel lesen | |
NUVALENT | 80,50 | 0,00 % | Goldman Sachs nimmt Nuvalent-Aktie mit Kaufempfehlung in die Bewertung auf | ||
RECURSION PHARMACEUTICALS | 5,210 | 0,00 % | Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? | ||
EVOTEC | 7,350 | +1,38 % | Evotec, Lanxess, Northern Data, Redcare Pharmacy, Renk Group, Vonovia - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
CG ONCOLOGY | 26,680 | +1,25 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
BEAM THERAPEUTICS | 19,890 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Beam Therapeutics mit Kursziel von 80 US-Dollar | ||
ENLIVEN THERAPEUTICS | 20,640 | +5,04 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
TREVI THERAPEUTICS | 5,980 | 0,00 % | Cantor Fitzgerald initiates coverage on Trevi Therapeutics stock with Overweight rating | ||
PHATHOM PHARMACEUTICALS | 8,910 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 22,650 | 0,00 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,010 | +1,48 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
TANGO THERAPEUTICS | 5,650 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung ... | BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen | |
IMMUNOME | 8,630 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
HARMONY BIOSCIENCES | 32,110 | 0,00 % | Pre-market Movers: Alti Global, CXApp, PAM Transportation Services, Harmony Biosciences, iCoreConnect | ROME (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 09.15 A.M. ET).In the Green CXApp Inc (CXAI) is up over 37% at $1.11.
PAM Transportation... ► Artikel lesen |